Trial Profile

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Ixazomib (Primary)
Indications Waldenstrom's macroglobulinaemia
Focus Therapeutic Use

Most Recent Events

07 Feb 2025 Planned End Date changed from 1 May 2025 to 11 Mar 2026.
13 Dec 2022 Preliminary results assessing efficacy of ixazomib and ibrutinib in patients with newly diagnosed as well as relapsed/refractory waldenstrom macroglobulinemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
03 Aug 2022 Status changed from suspended to active, no longer recruiting, according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com